Blood Markers Reveal Hidden Clues to PTSD Diagnosis and Treatment
Findings suggest blood tests could aid PTSD diagnosis, treatment, and even prevention efforts.
A new study found that people who are currently suffering or face a high risk of post-traumatic stress disorder show particular patterns in four biomarkers measurable with a simple blood test. The findings suggest these biomarkers could be used to predict a person’s likelihood of developing PTSD, diagnose the disorder, or monitor the response to treatment.
PTSD can occur after experiencing or witnessing a traumatic event. It is currently diagnosed based on symptoms such as flashbacks, difficulty sleeping or concentrating, negative thoughts, memory problems, and avoidance of triggering situations. Since other disorders can have some of these same symptoms, it can be challenging to diagnose PTSD and assess changes in response to treatment.
This research, which involved over 1,000 service members, represents the largest prospective study to date to assess the biological markers of PTSD over time.
“This study provides valuable insights into the natural history of PTSD and the effectiveness of interventions, which can inform the development of treatment guidelines and improve the care for individuals suffering from PTSD,” said Stacy-Ann Miller, a researcher at Walter Reed Army Institute of Research in Silver Spring, Maryland. “Better methods of predicting or screening for PTSD could help to overcome the disorder by identifying individuals at high risk of developing PTSD and providing them with early intervention or prevention strategies. This could potentially reduce the severity of symptoms or prevent the disorder from developing altogether.”
Miller presented the new research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, March 25–28 in Seattle.
Biomarkers, which reflect biological processes, can provide an objective measure of physiological changes associated with diseases such as PTSD. For the study, researchers analyzed four biomarkers in blood samples from active-duty service members taken before a 10-month deployment, three days after their return and three to six months after their return. The biomarkers have previously been linked to stress, depression, anxiety and mental health disorders. They included: the glycolytic ratio, a measure of how the body breaks down sugar to produce energy; arginine, an amino acid that plays a role in the immune and cardiovascular systems; serotonin, a chemical messenger that helps regulate mood, sleep and other functions; and glutamate, a chemical messenger that plays a role in learning and memory.
The researchers divided service members into groups based on measures of PTSD and mental resilience and compared the four biomarkers among the different groups. Participants were classified as having PTSD, sub-threshold PTSD or no PTSD depending on their clinical diagnosis and PTSD symptoms. Researchers classified participants’ resilience based on a combination of factors including PTSD, anxiety, sleep quality, alcohol use disorders, combat exposures, traumatic brain injury, and general physical and mental health. Previous studies have shown that people considered to have low resilience based on these measures are much more likely to develop PTSD after deployment than those with high resilience.
Comparing these biomarkers in people with different PTSD status and levels of resilience, the results showed that those with PTSD or sub-threshold PTSD had significantly higher glycolytic ratio and lower arginine than those with high resilience. People with PTSD also had significantly lower serotonin and higher glutamate than those with high resilience. These associations were independent of factors such as gender, age, body mass index, smoking and caffeine consumption.
The researchers said the biomarkers could help to predict which individuals face a high risk of PTSD, improve the accuracy of PTSD diagnosis and improve overall understanding of the drivers and effects of PTSD.
“Improved methods of screening and predicting PTSD could inform better treatment approaches by providing a deeper understanding of the underlying biological mechanisms of the disorder,” said Miller. “This could lead to the development of more targeted and effective treatments for PTSD or to identify specific subtypes of PTSD, which may respond differently to different treatments.”
Researchers cautioned that more research and validation would be needed to confirm the biomarkers’ utility in real-world settings.
Meeting: Discover BMB
The research was conducted in collaboration with the PTSD Systems Biology Consortium, a network of government and academic laboratories. Collaborators include Aarti Gautam, Ruoting Yang, Seid Muhie, Marti Jett and Rasha Hammamieh of the Walter Reed Army Institute of Research; Inyoul Lee, Kai Wang and Leroy Hood of the Institute for Systems Biology; Charles Marmar of New York University Langone Medical Center; Rachel Yehuda and Janine Florey of the Icahn School of Medicine at Mount Sinai; Synthia H. Mellon and Owen M. Wolkowitz of the University of California, San Francisco; Kerry Ressler and Francis J. Doyle III of Harvard University; and Bernie Daigle of the University of Memphis.